Improving depression and reducing cardiac events: Which is the chicken and which is the egg?

Journal of Psychosomatic Research

Volumn 74, Issue 5, 2013, Pages 454-457

  Ziegelstein, Roy C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR MORTALITY; DEPRESSION; HEART ARRHYTHMIA; HEART DISEASE; HEART MUSCLE; HUMAN; NOTE; OUTCOME ASSESSMENT; RECURRENT DISEASE; THROMBOSIS;

ANTIDEPRESSIVE AGENTS; CAUSE OF DEATH; CORONARY ARTERY DISEASE; DEPRESSIVE DISORDER; HUMANS; RECURRENCE; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VENTRICULAR FIBRILLATION;

EID: 84876708893     PISSN: 00223999     EISSN: 18791360     Source Type: Journal    
DOI: 10.1016/j.jpsychores.2013.02.005     Document Type: Note

References (41)

1. Ng DS, Wong NC, Hegele RA HDL-is it too big to fail?. Nat Rev Endocrinol 2013 Jan 15, [Epub ahead of print]. 10.1038/nrendo.2012.238.
2. Shapiro PA Depression treatment and coronary artery disease outcomes: time for reflection. J Psychosom Res 2013, 74:4-5.
3. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation 2003, 108:1664-1672.
4. Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Smith D, et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 2002, 106:2884-2887.
5. Schaar JA, De Korte CL, Mastik F, Strijder C, Pasterkamp G, Boersma E, et al. Characterizing vulnerable plaque features with intravascular elastography. Circulation 2003, 108:2636-2641.
6. Schaar JA, Regar E, Mastik F, McFadden EP, Saia F, Disco C, et al. Incidence of high-strain patterns in human coronary arteries: assessment with three-dimensional intravascular palpography and correlation with clinical presentation. Circulation 2004, 109:2716-2719.
7. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med 2011, 364:226-235. PROSPECT Investigators.
8. Stefanadis C, Diamantopoulos L, Dernellis J, Economou E, Tsiamis E, Toutouzas K, et al. Heat production of atherosclerotic plaques and inflammation assessed by the acute phase proteins in acute coronary syndromes. J Mol Cell Cardiol 2000, 32:43-52.
9. van Melle JP, de Jonge P, Honig A, Schene AH, Kuyper AM, Crijns HJ, et al. MIND-IT investigators. Effects of antidepressant treatment following myocardial infarction. Br J Psychiatry 2007, 190:460-466.
10. Berkman LF, Blumenthal J, Burg M, Carney RM, Catellier D, Cowan MJ, et al. Enhancing Recovery in Coronary Heart Disease Patients Investigators (ENRICHD). Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA 2003, 289:3106-3116.
11. Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT, et al. Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002, 288:701-709.
12. Kekow J, Moots R, Khandker R, Melin J, Freundlich B, Singh A Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis. Rheumatology (Oxford) 2011, 50:401-409.
13. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006, 367:29-35.
14. Krishnan R, Cella D, Leonardi C, Papp K, Gottlieb AB, Dunn M, et al. Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96weeks. Br J Dermatol 2007, 157:1275-1277.
15. Gniadecki R, Robertson D, Molta CT, Freundlich B, Pedersen R, Li W, et al. Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens. J Eur Acad Dermatol Venereol 2012, 26:1436-1443.
16. Frangogiannis NG, Smith CW, Entman ML The inflammatory response in myocardial infarction. Cardiovasc Res 2002, 53:31-47.
17. Biasucci LM, Vitelli A, Liuzzo G, Altamura S, Caligiuri G, Monaco C, et al. Elevated levels of interleukin-6 in unstable angina. Circulation 1996, 94:874-877.
18. Bozkurt B, Mann DL, Deswal A Biomarkers of inflammation in heart failure. Heart Fail Rev 2010, 15:331-341.
19. Ohtsuka T, Hamada M, Hiasa G, Sasaki O, Suzuki M, Hara Y, et al. Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol 2001, 37:412-417.
20. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, et al. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J Am Coll Cardiol 2000, 35:714-721.
21. Gullestad L, Aukrust P, Ueland T, Espevik T, Yee G, Vagelos R, et al. Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol 1999, 34:2061-2067.
22. Howren MB, Lamkin DM, Suls J Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009, 71:171-186.
23. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010, 67:446-457.
24. Müller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Müller B, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006, 11:680-684.
25. Parissis JT, Adamopoulus S, Rigas A, Kostakis G, Karatzas D, Venetsanou K, et al. Comparison of circulating proinflammatory cytokines and soluble apoptosis mediators in patients with chronic heart failure with versus without symptoms of depression. Am J Cardiol 2004, 94:1326-1328.
26. Marín F, Roldán V, Martínez JG, Hernández-Madrid A, Hernández-Romero D, Ortego M, et al. Influence of cardiac resynchronization therapy on indices of inflammation, the prothrombotic state and tissue remodeling in systolic heart failure: a pilot study. Thromb Res 2011, 128:391-394.
27. Theodorakis GN, Flevari P, Kroupis C, Adamopoulos S, Livanis EG, Kostopoulou A, et al. Antiinflammatory effects of cardiac resynchronization therapy in patients with chronic heart failure. Pacing Clin Electrophysiol 2006, 29:255-261.
28. Stanciu AE, Vatasescu RG, Stanciu MM, Iorgulescu C, Vasile AI, Dorobantu M Cardiac resynchronization therapy in patients with chronic heart failure is associated with anti-inflammatory and anti-remodeling effects. Clin Biochem 2013, 46:230-234.
29. Lappegård KT, Bjørnstad H Anti-inflammatory effect of cardiac resynchronization therapy. Pacing Clin Electrophysiol 2006, 29:753-758.
30. Michelucci A, Ricciardi G, Sofi F, Gori AM, Pirolo F, Pieragnoli P, et al. Relation of inflammatory status to major adverse cardiac events and reverse remodeling in patients undergoing cardiac resynchronization therapy. J Card Fail 2007, 13:207-210.
31. Ploux S, Verdoux H, Whinnett Z, Ritter P, Dos Santos P, Picard F, et al. Depression and severe heart failure: benefits of cardiac resynchronization therapy. J Cardiovasc Electrophysiol 2012, 23:631-636.
32. Boden WE Mounting evidence for lack of PCI benefit in stable ischemic heart disease: what more will it take to turn the tide of treatment?. Arch Intern Med 2012, 172:319-321.
33. Stevenson LW Inotropic therapy for heart failure. N Engl J Med 1998, 339:1848-1850.
34. Mukharji J, Rude RE, Poole WK, Gustafson N, Thomas LJ, Strauss HW, et al. The MILIS Study Group. Risk factors for sudden death after acute myocardial infarction: two-year follow-up. Am J Cardiol 1984, 54:31-36.
35. The Cardiac Arrhythmia Pilot Study (CAPS) Investigators Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS. Am J Cardiol 1988, 61:501-509.
36. The Cardiac Arrhythmia Suppression Trial II Investigators Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992, 327:227-233.
37. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991, 324:781-788. the CAST Investigators.
38. Budaj A, Cybulski J, Cedro K, Karczmarewicz S, Maciejewicz J, Wiśniewski M, et al. Effects of captopril on ventricular arrhythmias in the early and late phase of suspected acute myocardial infarction. Randomized, placebo-controlled substudy of ISIS-4. Eur Heart J 1996, 17:1506-1510.
39. Søgaard P, Gøtzsche CO, Ravkilde J, Nørgaard A, Thygesen K Ventricular arrhythmias in the acute and chronic phases after acute myocardial infarction. Effect of intervention with captopril. Circulation 1994, 90:101-107.
40. Epstein AE, Hallstrom AP, Rogers WJ, Liebson PR, Seals AA, Anderson JL, et al. Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST). JAMA 1993, 270:2451-2455.
41. Domanski MJ, Exner DV, Borkowf CB, Geller NL, Rosenberg Y, Pfeffer MA Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1999, 33:598-604.